1
|
Kahaleh AA, Ellington TM, Coker AO, Tillery E, Manasco KB, Truong HA, Kebodeaux CD, Edwards KL, Hayatshahi A, Gumina G, Hughes JA, Fuentes DG. Impact of COVID-19 on Pharmacy Education and Practice: Strategies to Boost Advocacy and Unity among Health Care Organizations. Am J Pharm Educ 2023; 87:100091. [PMID: 37953084 DOI: 10.1016/j.ajpe.2023.100091] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 02/24/2023] [Accepted: 03/06/2023] [Indexed: 11/14/2023]
Abstract
The global COVID-19 pandemic impacted pharmacy education and changed the pharmacists' scope of practice at the federal and state levels. Based on the Amended Public Readiness and Emergency Preparedness Act, pharmacists were authorized to provide essential services, including testing, treatments, and immunizations at various practice settings. Specifically, the United States Food and Drug Administration issued emergency use authorization for several medications, vaccines, and medical devices. The pandemic also affected the regulatory landscape for pharmacists, pharmacy education, access to care, and delivery of pharmacy services in-person and through telehealth. The pandemic's specific impact on pharmacy education heightened awareness of the well-being of the Academy. This commentary will highlight the impact of COVID-19 on both pharmacy education and practice. It will also provide strategies that educators, researchers, and practitioners can take into future research and action to help promote advocacy and unity among pharmacy organizations.
Collapse
Affiliation(s)
- Abby A Kahaleh
- Roosevelt University College of Science, Health, & Pharmacy, Schaumburg, IL, USA.
| | - Thomas M Ellington
- Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA
| | - Adeola O Coker
- University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA
| | - Erika Tillery
- Presbyterian College School of Pharmacy, Clinton, SC, USA
| | - Kalen B Manasco
- University of Florida College of Pharmacy, Gainesville, FL, USA
| | - Hoai-An Truong
- University of Maryland Eastern Shore, Princess Anne, MD, USA
| | | | - Krystal L Edwards
- Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, USA
| | | | | | - Jeremy A Hughes
- Chicago State University College of Pharmacy, Chicago, IL, USA
| | - David G Fuentes
- University of Portland School of Nursing and Health Innovations, Portland, OR, USA; American Journal of Pharmaceutical Education, USA
| |
Collapse
|
2
|
Kolluru S, Wanat MA, Ficzere CH, Akiyode O, Haber SL, Hayatshahi A, Caldwell D, Raman-Wilms L, Edwards KL. Review of Best Practices for Diversity, Equity, and Inclusion Committees Within Colleges of Pharmacy. Am J Pharm Educ 2023; 87:ajpe9043. [PMID: 36270665 PMCID: PMC10159040 DOI: 10.5688/ajpe9043] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 06/08/2022] [Indexed: 05/03/2023]
Abstract
Objective. To provide a review of best practices for diversity, equity, and inclusion (DEI) committees at United States colleges of pharmacy.Findings. In colleges of pharmacy, DEI committees can play a crucial role in promoting a culture change to ensure pharmacy graduates are equipped to provide equitable and representative care for the patients they serve. There is limited literature available on DEI committee composition, roles, and responsibilities, and their place within a college of pharmacy's organizational structure. A commitment to DEI should be part of the college's strategic plan and embedded and supported at all levels of the college and university to ensure success of DEI-related strategic initiatives. For a DEI committee to be effective, its composition should be intentional to include change agents, campus leaders, and members who are passionate and knowledgeable to execute the DEI goals. For sustainable change, involvement of the entire learning community and an organizational culture change is also important. Thus, DEI committees need to establish active bidirectional collaborations and communication with all key committees, offices, community leaders, and alumni to implement diversity goals.Summary. The DEI committee's established place in the organizational structure of the college is essential to ensure fair and appropriate representation of the community it serves. A clearly defined DEI committee with committee composition, roles, responsibilities, and its association with all constituents of the college and community can help achieve its intended strategic goals.
Collapse
Affiliation(s)
- Srikanth Kolluru
- KGI School of Pharmacy and Health Sciences, Claremont, California
| | | | - Cathy H Ficzere
- Belmont University, College of Pharmacy, Nashville, Tennessee
| | - Oluwaranti Akiyode
- Howard University, College of Pharmacy, Washington, District of Columbia
| | - Stacy L Haber
- Midwestern University, College of Pharmacy, Glendale Campus, Glendale, Arizona
| | | | - David Caldwell
- University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas
| | - Lalitha Raman-Wilms
- University of Manitoba, College of Pharmacy, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada
| | - Krystal L Edwards
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Dallas, Texas
| |
Collapse
|
3
|
Bzowyckyj AS, Blake E, Crabtree B, Edwards KL, Franks AM, Gonyeau M, Rospond R, Turner K, Gandhi N, Ragucci K. Advancing Pharmacy Education and Workforce Development Amid the COVID-19 Pandemic: Report of the 2020-2021 AACP Academic Affairs Committee. Am J Pharm Educ 2021; 85:8716. [PMID: 34301580 PMCID: PMC8715966 DOI: 10.5688/ajpe8716] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
EXECUTIVE SUMMARY The 2020-2021 Academic Affairs Committee was charged to (1) Read all six reports from the 2019-20 AACP standing committees to identify elements of these reports that are relevant to your committee's work this year; (2) Determine what changes made in colleges and schools of pharmacy during the COVID-19 pandemic should be continued to advance pharmacy education; (3) Develop a realistic model for colleges and schools of pharmacy to share resources to meet the curricular needs of member schools; (4) Create strategies by which colleges and schools of pharmacy can meet current and future workforce development needs particularly in light of the changes in healthcare delivery as a result of the COVID-19 pandemic; (5) Identify salient activities for the Center To Accelerate Pharmacy Practice Transformation and Academic Innovation (CTAP) for consideration by the AACP Strategic Planning Committee and AACP staff. This report provides an overview of changes made in schools and colleges of pharmacy implemented in response to the COVID-19 pandemic that may be continued to advance pharmacy education; a realistic model for colleges and schools of pharmacy to share resources to meet the curricular needs of member schools; and strategies by which schools and colleges of pharmacy can meet current and future workforce development needs, particularly in light of the changes in healthcare delivery as a result of the COVID-19 pandemic. The committee is proposing one policy statement for consideration by the 2021 AACP House of Delegates, four suggestions for consideration by schools and colleges of pharmacy (including two endorsements for suggestions from the 2020-21 Argus Commission), and one recommendation for consideration by AACP for CTAP to implement and oversee.
Collapse
Affiliation(s)
| | - Elizabeth Blake
- University of South Carolina, College of Pharmacy, Columbia, South Carolina
| | - Brian Crabtree
- Mercer University, College of Pharmacy, Atlanta, Georgia
| | - Krystal L Edwards
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, Dallas, Texas
| | - Amy M Franks
- University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas
| | - Michael Gonyeau
- Northeastern University, Bouvé College of Health Sciences, School of Pharmacy, Boston, Massachusetts
| | - Raylene Rospond
- Manchester University, College of Pharmacy and Health Sciences, Fort Wayne, Indiana
| | - Kyle Turner
- University of Utah, College of Pharmacy, Salt Lake City, Utah
| | - Nidhi Gandhi
- American Association of Colleges of Pharmacy, Arlington, Virginia
| | - Kelly Ragucci
- American Association of Colleges of Pharmacy, Arlington, Virginia
| |
Collapse
|
4
|
Baruwal S, Hall RG, Pass SE, Safri A, Edwards KL. Efficacy and benefits of mock residency interviews. Curr Pharm Teach Learn 2021; 13:958-963. [PMID: 34294260 DOI: 10.1016/j.cptl.2021.06.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 01/25/2021] [Accepted: 06/22/2021] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Obtaining a residency has become more competitive as more pharmacy students seek postgraduate training. This is likely due to pharmacist positions increasing in clinical settings. To be fully prepared, students seeking residency positions should be trained for the interview process by their pharmacy school. METHODS Mock residency interviews (MRI) were conducted at the Texas Tech University Health Sciences Center School of Pharmacy which included components of typical residency interviews. The primary outcome compared residency match rates for MRI participants vs. non-participants. Secondary outcomes evaluated student preparedness, student and faculty feedback, and satisfaction/benefit of the event along with comparison of school vs. national match rate and assessment of those matching compared to grade point average (GPA). RESULTS Match rates were similar between MRI participants vs. non-participants (75% vs. 73%) with significant difference in Phase I match rates between MRI participants vs. non-participants (75% vs. 51%, P = .007). MRI was significantly associated with Phase I matching in the multivariable analysis (odds ratio (OR) = 2.81, 95% CI 1.27-6.22). The overall school's match rate exceeded the national two out of three years in the quality improvement project period. GPA was the only other factor independently associated with Phase I matching (OR = 1.15, 95% CI 1.01-1.32). Students and faculty consistently reported positive feedback following participation. CONCLUSIONS MRI are valuable and are making a difference as indicated by improved Phase I match rates for those that participated. Students and faculty reported an increase in preparedness and overall satisfaction after attending MRI.
Collapse
Affiliation(s)
- Samichhya Baruwal
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Suite 500, Dallas, TX 75235, United States.
| | - Ronald G Hall
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Suite 500, Dallas, TX 75235, United States.
| | - Steven E Pass
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Suite 500, Dallas, TX 75235, United States.
| | - Ana Safri
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Suite 500, Dallas, TX 75235, United States.
| | - Krystal L Edwards
- Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Suite 500, Dallas, TX 75235, United States.
| |
Collapse
|
5
|
Irons BK, Edwards KL, Chastain LM, Black RL, Brown CD, Seifert CF. Assessment of a didactic ambulatory care pharmacy elective on student perceptions and subsequent performance in an ambulatory care advanced pharmacy practice experience. Curr Pharm Teach Learn 2018; 10:1211-1218. [PMID: 30497624 DOI: 10.1016/j.cptl.2018.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Revised: 03/07/2018] [Accepted: 06/07/2018] [Indexed: 06/09/2023]
Abstract
INTRODUCTION This study assessed student perception in treating chronic disease states before and after taking an ambulatory care didactic elective and the impact on performance within a fourth-year ambulatory care advanced pharmacy practice experience (APPE). METHODS Assessment of student perceptions was evaluated in students taking the Fall 2016 and Spring 2017 elective offering by completing an 11-item electronic survey prior to the first lecture of the course and after the last lecture of the course. A retrospective assessment of student performance in the APPE compared students that had taken the elective to those that had not over a two-and-one-half year period. Data collected included the students' final APPE experiential and required examination grade. RESULTS In all but one survey question, student perceptions significantly improved upon completion of the elective. Student ambulatory care APPE final experiential grades were higher in students who had taken the elective compared to those that had not (90.3% vs. 88.9%, respectively, p = 0.04) as were APPE examination scores (78.0% vs. 74.0%, respectively, p = 0.01). DISCUSSION AND CONCLUSIONS Student perception in key ambulatory care concepts, disease states, and drug knowledge improved after taking the ambulatory care elective. Student ambulatory care APPE performance was also mildly improved as a result of taking the elective compared to those who did not take the course. This is the first study to evaluate subsequent performance in an APPE as a result of taking an elective ambulatory care course and can serve as a template for other research in elective assessment.
Collapse
Affiliation(s)
- Brian K Irons
- Texas Tech University Health Sciences Center School of Pharmacy, 3601 4th St. Lubbock, TX 79430, United States.
| | - Krystal L Edwards
- Texas Tech University Health Sciences Center School of Pharmacy, 4500 S. Lancaster Rd, Dallas, TX 75316, United States.
| | - Lisa M Chastain
- Texas Tech University Health Sciences Center School of Pharmacy, 4500 S. Lancaster Rd, Dallas, TX 75316, United States.
| | - Robin L Black
- Texas Tech University Health Sciences Center School of Pharmacy, 4500 S. Lancaster Rd, Dallas, TX 75316, United States.
| | - Crystal D Brown
- Texas Tech University Health Sciences Center School of Pharmacy, 4500 S. Lancaster Rd, Dallas, TX 75316, United States
| | - Charles F Seifert
- Texas Tech University Health Sciences Center School of Pharmacy, 3601 4th St. Lubbock, TX 79430, United States.
| |
Collapse
|
6
|
Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol 2018; 11:1179552218787502. [PMID: 30013416 PMCID: PMC6043943 DOI: 10.1177/1179552218787502] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 06/12/2018] [Indexed: 12/20/2022]
Abstract
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is a common complication in patients with metabolic syndrome. The role of statin therapy specifically for the treatment of NAFLD remains unknown. The aim of this review is to discuss outcomes of recent articles analyzing statin therapy in patients with NAFLD. FINDINGS A total of 12 trials met the inclusion criteria. Statins were not found to increase the prevalence of NAFLD once confounding variables were considered. Statins were also found to be beneficial in treating dyslipidemia and improving liver function. Histological liver outcomes in patients with NAFLD were controversial. One trial found a reduction in the incidence of hepatocellular carcinoma associated with the use of statins. CONCLUSIONS Overall, therapy with statins appears to be safe for use in patients with NAFLD. Several trials have validated the use of statins for the treatment of dyslipidemia; however, it remains unknown as to whether statins should be used to specifically treat NAFLD.
Collapse
Affiliation(s)
- Meredith A Sigler
- Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Lee Congdon
- School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Krystal L Edwards
- Office of Professional Affairs, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| |
Collapse
|
7
|
Abstract
The purpose of this study was to evaluate the effects of alternative antihyperglycemic therapy after discontinuation of metformin due to documented declining renal function. This retrospective, single-site study evaluated patients who had metformin discontinued between 1 January 1999 and 30 September 2013. Medical records were evaluated for documented adverse events, subsequent glycemic control, and costs associated with the alternative therapy. Patients served as their own controls. A total of 179 patients met study entry criteria, and their peak A1C was significantly higher within the year after metformin discontinuation (P <0.001). After the provider added new medications to control patients' blood glucose, their A1C by the end of the first year after discontinuing metformin was similar to their A1C while taking metformin. Significant weight gain accompanied the use of the medications added to replace metformin, with an average increase of 3.81 kg (P <0.001). Additionally, after discontinuing metformin, more patients experienced hypoglycemia with the addition of other medications to control their blood glucose (P <0.001). As expected, the cost of therapy was significantly higher (P <0.0001) after metformin was discontinued because metformin was generically available, whereas the replacement medications frequently were not. Providers should consider the expanded recommendations for the use of metformin in patients with mild to moderate stable renal dysfunction to help such patients avoid weight gain, hypoglycemia, loss of blood glucose control, and increased costs.
Collapse
Affiliation(s)
| | - Krystal L. Edwards
- Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX
| | | | | | - Kevin C. Kelly
- North Texas Veterans Affairs Health Care System, Dallas, TX
| |
Collapse
|
8
|
Pearson RG, Clement RGE, Edwards KL, Scammell BE. Do smokers have greater risk of delayed and non-union after fracture, osteotomy and arthrodesis? A systematic review with meta-analysis. BMJ Open 2016; 6:e010303. [PMID: 28186922 PMCID: PMC5129177 DOI: 10.2106/jbjs.f.00186 10.1136/bmjopen-2015-010303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 09/21/2016] [Accepted: 09/29/2016] [Indexed: 09/17/2023] Open
Abstract
OBJECTIVES Systematic review and meta-analysis of published observational cohort studies. To quantify the increased risk smokers have of experiencing a delayed and/or non-union in fractures, spinal fusion, osteotomy, arthrodesis or established non-unions. SETTING Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Allied and Complementary Medicine Database (AMED) and Web of Science Core Collection from 1966 to 2015. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND INTERVENTIONS Observational cohort studies that reported adult smokers and non-smokers with delayed and/or non-union or time to union of the fracture, spinal fusion, osteotomy, arthrodesis or established non-union were eligible. DATA EXTRACTION AND OUTCOME MEASURES 2 authors screen titles, abstracts and full papers. Data were extracted by 1 author and checked independently by a second. The relative risk ratios of smoking versus non-smoking and the mean difference in time to union patients developing a delayed and/or non-union were calculated. RESULTS The search identified 3013 articles; of which, 40 studies were included. The meta-analysis of 7516 procedures revealed that smoking is linked to an increased risk of delayed and/or non-union. When considered collectively, smokers have 2.2 (1.9 to 2.6) times the risk of experiencing delayed and/or non-union. In all the subgroups, the increased risk was always ≥1.6 times that of non-smokers. In the patients where union did occur, it was a longer process in the smokers. The data from 923 procedures were included and revealed an increase in time to union of 27.7 days (14.2 to 41.3). CONCLUSIONS Smokers have twice the risk of experiencing a non-union after fracture, spinal fusion, osteotomy, arthrodesis or treatment of non-union. Time to union following fracture, osteotomy, arthrodesis or treatment of an established non-union is longer in smokers. Smokers should be encouraged to abstain from smoking to improve the outcome of these orthopaedic treatments.
Collapse
Affiliation(s)
- R G Pearson
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - R G E Clement
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - K L Edwards
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - B E Scammell
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| |
Collapse
|
9
|
Abstract
OBJECTIVES Systematic review and meta-analysis of published observational cohort studies. To quantify the increased risk smokers have of experiencing a delayed and/or non-union in fractures, spinal fusion, osteotomy, arthrodesis or established non-unions. SETTING Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Allied and Complementary Medicine Database (AMED) and Web of Science Core Collection from 1966 to 2015. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND INTERVENTIONS Observational cohort studies that reported adult smokers and non-smokers with delayed and/or non-union or time to union of the fracture, spinal fusion, osteotomy, arthrodesis or established non-union were eligible. DATA EXTRACTION AND OUTCOME MEASURES 2 authors screen titles, abstracts and full papers. Data were extracted by 1 author and checked independently by a second. The relative risk ratios of smoking versus non-smoking and the mean difference in time to union patients developing a delayed and/or non-union were calculated. RESULTS The search identified 3013 articles; of which, 40 studies were included. The meta-analysis of 7516 procedures revealed that smoking is linked to an increased risk of delayed and/or non-union. When considered collectively, smokers have 2.2 (1.9 to 2.6) times the risk of experiencing delayed and/or non-union. In all the subgroups, the increased risk was always ≥1.6 times that of non-smokers. In the patients where union did occur, it was a longer process in the smokers. The data from 923 procedures were included and revealed an increase in time to union of 27.7 days (14.2 to 41.3). CONCLUSIONS Smokers have twice the risk of experiencing a non-union after fracture, spinal fusion, osteotomy, arthrodesis or treatment of non-union. Time to union following fracture, osteotomy, arthrodesis or treatment of an established non-union is longer in smokers. Smokers should be encouraged to abstain from smoking to improve the outcome of these orthopaedic treatments.
Collapse
Affiliation(s)
- R G Pearson
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - R G E Clement
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - K L Edwards
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| | - B E Scammell
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK
| |
Collapse
|
10
|
Morris MA, Clarke GP, Hulme C, Edwards KL, Aggarwal A, Drewnowski A, Mishra GD, Jackson CA, Cade JE. P64 Exploring weight status in Australia and the US: a cross-sectional analysis using a commercial geodemographic classification. Br J Soc Med 2016. [DOI: 10.1136/jech-2016-208064.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Edwards KL, Hadley RL, Baby N, Yeary JC, Chastain LM, Brown CD. Utilizing Clinical Pharmacy Specialists to Address Access to Care Barriers in the Veteran Population for the Management of Diabetes. J Pharm Pract 2016; 30:412-418. [PMID: 27568478 DOI: 10.1177/0897190016663952] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To show that clinical pharmacy specialists (CPSs) can be utilized in remote facilities to provide appropriate diabetes outcomes along with potential cost savings. METHODS A retrospective cohort chart review conducted at the Veterans Affairs North Texas Healthcare System (VANTHCS) evaluated outcomes in patients with type 2 diabetes mellitus referred to CPSs at Fort Worth Outpatient Clinic (FWOPC) or the endocrinologist-managed specialty clinic at the Dallas VA Medical Center (DVAMC). The primary outcome was percentage of patients reaching hemoglobin A1c (HbA1c) goal of <8%. Secondary outcomes were percentage of patients reaching HbA1c <7%, time to reach HbA1c goals of <8% and <7%, and cost savings. RESULTS There was no statistically significant difference in the number of patients reaching HbA1c goal <8% in the FWOPC (65.3%) compared to the DVAMC (55.8%). Secondary end points comparing FWOPC and DVAMC found no difference in patients reaching HbA1c <7% (20.8% vs 19.2%) and time to reach HbA1c goal of <8% (4.5 vs 6 months) and <7% (8.5 vs 7.5 months). Cost-saving analysis demonstrated a composite of US$350 292 could be saved by the VANTHCS facility if patients continued to be referred to CPS. CONCLUSION CPSs can be utilized in diabetes management to provide similar health outcomes as the endocrinologist-managed clinic and to potentially allow for facility cost savings.
Collapse
Affiliation(s)
- Krystal L Edwards
- 1 Department of Pharmacy Practice, Ambulatory Care Division, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Ryan L Hadley
- 2 PGY2 Ambulatory Care Pharmacy Resident, Veterans Affairs North Texas Health Care System, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Nidhu Baby
- 3 School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Julianne C Yeary
- 4 PGY2 Critical Care Pharmacy Resident, West Virginia University Medicine, WV, USA
| | - Lisa M Chastain
- 5 Department of Pharmacy Practice, Ambulatory Care Division, Veterans Affairs North Texas Health Care System, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Crystal D Brown
- 5 Department of Pharmacy Practice, Ambulatory Care Division, Veterans Affairs North Texas Health Care System, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| |
Collapse
|
12
|
Sorensen TD, Shapiro NL, Benedict N, Edwards KL, Chan A, Covey D, Daniels C, Hagemann T, Hemstreet B, Miller W, Musselman ME. Recommendations for Aligning PGY2 Pharmacy Residency Training and Pharmacy Specialist Board Certification. Pharmacotherapy 2016; 36:e34-9. [PMID: 27062513 DOI: 10.1002/phar.1741] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
With the increased focus and anticipated growth in specialty training and certification within the profession of pharmacy, it is important for the profession to step back and evaluate the manner in which its adopted education and certification systems interface. As a result of specialty practice development, significant growth is occurring in both postgraduate year two (PGY2) pharmacy residency programs and individuals seeking certification by the Board of Pharmacy Specialties. As the profession continues to evolve its specialty training and credentialing systems, it is important to consider the inherent relationship between these systems. This paper considers the current landscape of specialty training and certification, including issues related to the quality of PGY2 training, consistent application of standards across and within PGY2 programs, credentialing of preceptors and program directors, and alignment of training with specialty certification examination content domains. We outline recommendations across three areas: (1) creating consistency between specialty training and certification, (2) aligning qualifications of PGY2 residency program directors and preceptors with the designated specialty area, and (3) assessing program quality in the context of the expectations of specialists established by the profession. The goal of this paper is to stimulate professional dialogue on these issues. Establishing both formal and informal connections between specialty training and certification can serve as the foundation for a rational approach to professional development and the credentialing that will be recognized by stakeholders outside the pharmacy profession. Establishing these connections will also support and advance the profession's mission of meeting the medication needs of patients.
Collapse
|
13
|
Abstract
Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of agents in treating type 2 diabetes via an insulin independent mechanism to lower blood glucose. Currently marketed agents, including canagliflozin, dapagliflozin, empagliflozin, and luseogliflozin, reduce hemoglobin A1c (HbA1c) ~0.8-1%, reduce fasting and post prandial glucose, and have little hypoglycemia associated with them when added to therapies including metformin, a sulfonylurea, pioglitazone, or insulin. Patients receiving SGLT-2 inhibitors have reduced weight and blood pressure, but are more susceptible to urinary tract infections and genital mycotic infections. This review summarizes current literature regarding the SGLT-2 inhibitors.
Collapse
Affiliation(s)
- Molly G Minze
- a School of Pharmacy - Pharmacy Practice , Texas Tech University Health Sciences Center , Abilene , TX , USA
| | - Robin L Koffarnus
- b School of Pharmacy - Pharmacy Practice , Texas Tech University Health Sciences Center , Dallas , TX , USA
| | - Trista A Bailey
- a School of Pharmacy - Pharmacy Practice , Texas Tech University Health Sciences Center , Abilene , TX , USA
| | - Sandy Diec
- a School of Pharmacy - Pharmacy Practice , Texas Tech University Health Sciences Center , Abilene , TX , USA
| | - Krystal L Edwards
- b School of Pharmacy - Pharmacy Practice , Texas Tech University Health Sciences Center , Dallas , TX , USA
| |
Collapse
|
14
|
Greenfield JRF, Almond M, Clarke GP, Edwards KL. Factors affecting school physical education provision in England: a cross-sectional analysis. J Public Health (Oxf) 2015; 38:316-22. [PMID: 25795654 DOI: 10.1093/pubmed/fdv032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Attitudes towards physical activity are largely developed during childhood meaning that school physical education classes can have a strong influence. METHODS National level data of school pupils (n = 21 515) in England were analysed to examine the association between school provision of physical education with sex, age, geographic and socioeconomic factors. RESULTS Children attending independent schools had more scheduled physical education time (P < 0.001; 95% confidence interval (CI) 18 to 30 extra min per week). This association was true for males (P = 0.024); schools located in the South (P < 0.001; 95% CI 2 to 3) and rural areas (P < 0.001; 95% CI 3 to 5); or with a higher percentage of pupils eligible for free school meals (P < 0.001; 95% CI 3 to 4). Schools in more affluent areas (P < 0.001; 95% CI -1 to -2) and those with lower percentages of pupils from ethnic minorities (P < 0.001; 95% CI -1 to -2) also had higher minutes of physical education provision per week. Regarding age, 93% of schools met the guidelines in Years 1-9; only 45% did in Years 10-13. CONCLUSION Differences in physical education were found in relation to school type, socioeconomic status and geographical factors. Age-related differences in compliance with guidelines are of concern; ways to increase provision for older children should be investigated.
Collapse
Affiliation(s)
- J R F Greenfield
- Academic Orthopaedics Trauma and Sports Medicine, School of Medicine, University of Nottingham, Floor C, West Block, Queens Medical Centre, Nottingham NG7 2UH, UK UFR STAPS, Université de Reims Champagne-Ardenne, 51100 Reims, France
| | - M Almond
- School of Geography, University of Leeds, Leeds LS2 9JT, UK
| | - G P Clarke
- School of Geography, University of Leeds, Leeds LS2 9JT, UK
| | - K L Edwards
- Academic Orthopaedics Trauma and Sports Medicine, School of Medicine, University of Nottingham, Floor C, West Block, Queens Medical Centre, Nottingham NG7 2UH, UK
| |
Collapse
|
15
|
Abstract
Introduction As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved. Aims This article examines the evidence currently available on the efficacy and safety of dulaglutide for use in T2DM. Evidence review Dulaglutide has been shown to have similar efficacy and safety to other newer GLP-1 RAs, and better glycemic control than placebo. It lowers glycated hemoglobin (A1c), fasting and postprandial glucose levels, and promotes weight loss when used as first-, second-, or third-line therapy. It has also been shown to improve β-cell function and provide cardiovascular benefits, such as lower blood pressure and improved lipid levels. Dulaglutide also has a low risk for hypoglycemia and a similar adverse effect profile to other GLP-1 RAs in the class, with transient gastrointestinal problems and potential risk for pancreatitis. Place in therapy While long-term data on safety and efficacy are forthcoming, dulaglutide is positioned to be placed at the same level as other GLP-1 RAs in the class: as second-line therapy in addition to diet and exercise in those patients who cannot achieve glycemic control on monotherapy metformin. It may also be useful as first-line therapy instead of metformin. Conclusion Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class.
Collapse
Affiliation(s)
- Krystal L Edwards
- Ambulatory Care Division, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Molly G Minze
- Ambulatory Care Division, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA
| |
Collapse
|
16
|
Edwards KL, Schizas C, Mannion AF, Aebi M, Gunzburg R. How to be a good reviewer. Eur Spine J 2014; 24:1-2. [PMID: 25510517 DOI: 10.1007/s00586-014-3719-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Indexed: 11/30/2022]
Affiliation(s)
- K L Edwards
- School of Medicine, University of Nottingham, Nottingham, UK,
| | | | | | | | | |
Collapse
|
17
|
Abstract
PURPOSE Current evidence on statin agents as potential alternatives or adjuncts to corticosteroid therapy for asthma is reviewed. SUMMARY Research showing antiinflammatory and antioxidant effects of statins in animal models suggested that the cholesterol-lowering drugs might be useful in mitigating the adverse effects of long-term corticosteroid therapy in patients with asthma, but studies in humans have yielded mixed results. Two small placebo-controlled clinical trials indicated that statins were not effective in combating asthmatic inflammatory processes, and trials of statins as adjunctive therapy have indicated minimal steroid-sparing benefits. In two studies involving a total of more than 1000 current and former smokers with asthma, statin use correlated with reduced acute asthma exacerbations and a slower decline of lung function in some patients. A large population-based study (n = 3965) found that statin therapy was associated with a significantly reduced risk of hospitalization for asthma after an average follow-up period of about 4.5 years; a smaller U.S. retrospective cohort study indicated a significantly lower 1-year rate of asthma-related emergency room visits among patients receiving statins relative to those not using statins (9.08% versus 4.18%). Much of the research on statins and asthma has not controlled for confounding influences such as patient comorbidities and concomitant medication use. CONCLUSION Clinical trials have shown that statin therapy is not superior to and does not enhance the beneficial effects of inhaled corticosteroids for the treatment of asthma. Some evidence suggests that statins may help preserve lung function in cigarette smokers with obstructive pulmonary disease and reduce hospitalizations in asthmatic smokers and nonsmokers.
Collapse
Affiliation(s)
- Derrica Y Walker
- Derrica Y. Walker is a 2014 Pharm.D candidate; and Krystal L. Edwards, Pharm.D., FCCP, BCPS, is Associate Professor, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas
| | | |
Collapse
|
18
|
Quraishi NA, Ramoutar D, Sureshkumar D, Manoharan SR, Spencer A, Arealis G, Edwards KL, Boszczyk BM. Metastatic spinal cord compression as a result of the unknown primary tumour. Eur Spine J 2014; 23:1502-7. [PMID: 24691912 DOI: 10.1007/s00586-014-3274-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Revised: 02/27/2014] [Accepted: 03/13/2014] [Indexed: 02/06/2023]
Abstract
PURPOSE Patients presenting with metastatic spinal cord compression (MSCC) due to an unknown primary tumour (UPT) present an interesting problem with limited literature available to provide guidance on management. Our aim was twofold-first, to analyse all our patients with MSCC due to a UPT pre-operatively, to review their treatment and outcome; second, make comparisons with those patients who presented with MSCC due to a known primary tumour (KPT) during the same period. METHODS All data was collected retrospectively from October 2004 to October 2009, then prospectively from October 2009 to October 2012 (8 years). We reviewed all patient records held on the database, including patient demographics, primary tumour, neurological outcome (Frankel grade), complications and survival. RESULTS During the 8-year study period, out of the 382 patients who underwent emergency surgery for MSCC, 285 patients were included in whom complete information was available. Of these, 17 patients presented with MSCC due to a UPT (6 %; mean age 61 years, 5 M, 12 F). When compared to those with a known primary, the UPT group trended to a longer duration of symptoms prior to surgery (200 vs. 156 days, p = 0.86). They had a similar neurological outcome (88 % remained the same or improved post-operatively vs. 90 % in KPT group; p = 0.42), similar complication rate (23.5 vs. 33.6 %; p = 0.32) and survival (222 vs. 251 days, p = 0.42). The primary site in the UPT group was confirmed in 10/17 (58.8 %)-all 10 were adenocarcinoma [lung (6) and GI (4)]. DISCUSSION In our series, the incidence of MSCC due to an unknown primary was 6 %. They had similar overall outcome (neurology post-operatively, complications and survival) to those patients with MSCC from a known primary. Our experience would suggest that we need to treat these patients expeditiously with thorough evaluation and urgent treatment.
Collapse
Affiliation(s)
- N A Quraishi
- Centre for Spine Studies and Surgery, West Block, D Floor, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK,
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Edwards KL, Salvo MC, Ward KE, Attridge RT, Kiser K, Pinner NA, Gallegos PJ, Kesteloot LL, Hylton A, Bookstaver PB. Assessment and revision of clinical pharmacy practice internet web sites. Ann Pharmacother 2013; 48:258-67. [PMID: 24259640 DOI: 10.1177/1060028013510899] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Health care professionals, trainees, and patients use the Internet extensively. Editable Web sites may contain inaccurate, incomplete, and/or outdated information that may mislead the public's perception of the topic. OBJECTIVE To evaluate the editable, online descriptions of clinical pharmacy and pharmacist and attempt to improve their accuracy. METHODS The authors identified key areas within clinical pharmacy to evaluate for accuracy and appropriateness on the Internet. Current descriptions that were reviewed on public domain Web sites included: (1) clinical pharmacy and the clinical pharmacist, (2) pharmacy education, (3) clinical pharmacy and development and provision for reimbursement, (4) clinical pharmacists and advanced specialty certifications/training opportunities, (5) pharmacists and advocacy, and (6) clinical pharmacists and interdisciplinary/interprofessional content. The authors assessed each content area to determine accuracy and prioritized the need for updating, when applicable, to achieve consistency in descriptions and relevancy. The authors found that Wikipedia, a public domain that allows users to update, was consistently the most common Web site produced in search results. RESULTS The authors' evaluation resulted in the creation or revision of 14 Wikipedia Web pages. However, rejection of 3 proposed newly created Web pages affected the authors' ability to address identified content areas with deficiencies and/or inaccuracies. CONCLUSIONS Through assessing and updating editable Web sites, the authors strengthened the online representation of clinical pharmacy in a clear, cohesive, and accurate manner. However, ongoing assessments of the Internet are continually needed to ensure accuracy and appropriateness.
Collapse
Affiliation(s)
- Krystal L Edwards
- Texas Tech School of Pharmacy-Dallas/Fort Worth Campus, Dallas, TX, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
PURPOSE The purpose of this study was to investigate if patients of nonwhite race are less likely to receive insulin therapy for treatment of poorly controlled diabetes than patients of white race. METHODS A retrospective review was performed of patients with an A1C >10%. The primary objective was to determine any difference in the initiation of insulin between white and nonwhite patients. Secondary outcomes measured the impact of clinic type and provider specialty on the initiation of insulin therapy. Exclusion criteria included those patients with type 1 diabetes mellitus, those who were previously receiving insulin, and those without an outpatient clinic visit within 14 days of an A1C >10%. RESULTS A total of 277 patients were included. Of these patients, 132 (47.7%) were white, followed by 95 (34.2%) black non-Hispanic patients and 30 (10.8%) Hispanic/Latino patients. No difference was found in receipt of insulin therapy for nonwhite patients as compared to white patients (12.5 vs 21.4, P = .117). Neither clinic type nor provider specialty impacted initiation of insulin therapy. No changes to medication regimen were made at 35% of clinic visits. CONCLUSIONS Failure to intensify diabetic medications was common in this outpatient setting. There were no disparities in the receipt of insulin therapy between white and nonwhite patients.
Collapse
Affiliation(s)
- Katura C Bullock
- Texas Tech University Health Sciences Center School of Pharmacy, Department of Pharmacy Practice; Veterans Affairs North Texas Health
Care System (VANTHCS), Dallas, Texas (Dr Bullock, Dr Edwards, Dr Greene, Dr Shah, Dr Blaszczyk)
| | - Krystal L Edwards
- Texas Tech University Health Sciences Center School of Pharmacy, Department of Pharmacy Practice; Veterans Affairs North Texas Health
Care System (VANTHCS), Dallas, Texas (Dr Bullock, Dr Edwards, Dr Greene, Dr Shah, Dr Blaszczyk)
| | - Ronald Shane Greene
- Texas Tech University Health Sciences Center School of Pharmacy, Department of Pharmacy Practice; Veterans Affairs North Texas Health
Care System (VANTHCS), Dallas, Texas (Dr Bullock, Dr Edwards, Dr Greene, Dr Shah, Dr Blaszczyk)
| | - Sachin R Shah
- Texas Tech University Health Sciences Center School of Pharmacy, Department of Pharmacy Practice; Veterans Affairs North Texas Health
Care System (VANTHCS), Dallas, Texas (Dr Bullock, Dr Edwards, Dr Greene, Dr Shah, Dr Blaszczyk)
| | - Amie Taggart Blaszczyk
- Texas Tech University Health Sciences Center School of Pharmacy, Department of Pharmacy Practice; Veterans Affairs North Texas Health
Care System (VANTHCS), Dallas, Texas (Dr Bullock, Dr Edwards, Dr Greene, Dr Shah, Dr Blaszczyk)
| |
Collapse
|
21
|
Quraishi NA, Manoharan SR, Arealis G, Khurana A, Elsayed S, Edwards KL, Boszczyk BM. Accuracy of the revised Tokuhashi score in predicting survival in patients with metastatic spinal cord compression (MSCC). Eur Spine J 2013; 22 Suppl 1:S21-6. [PMID: 23328875 DOI: 10.1007/s00586-012-2649-5] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Revised: 12/13/2012] [Accepted: 12/23/2012] [Indexed: 01/09/2023]
Abstract
PURPOSE The revised Tokuhashi score has been widely used to evaluate indications for surgery and predict survival in patients with metastatic spinal disease. Our aim was to analyse the actual survival time of patients treated for metastatic spinal cord compression (MSCC) in comparison with the predicted survival based on the revised Tokuhashi score. This would thereby allow us to determine the overall predictive value of this scoring system. METHODS This study was a semi-prospective clinical study of all patients with MSCC presenting to our unit over 8 years-data from October 2003 to December 2009 were collected retrospectively and from December 2009, all data collected prospectively to October 2011. Patients were divided into three groups--Group 1 (Tokuhashi score 0-8, n = 84), Group 2 (Tokuhashi score 9-11, n = 83) and Group 3 (Tokuhashi score 12-15, n = 34). Data collected included demographic data, primary tumour histology, surgery type and complications, neurological outcome (Frankel grade) and survival. RESULTS A total of 233 patients with MSCC were managed surgically in our unit during this time. Out of these complete data were available on 201 patients for analysis. Mean age of patients was 61 years (range 18-86; 127 M, 74 F). The primary tumour type was Breast (n = 29, 15 %), Haematological (n = 28, 14 %), Renal (n = 26, 13 %), Prostate (n = 26, 13 %), Lung (n = 23, 11 %), Gastro-intestinal (n = 11, 5 %), Sarcoma (n = 9, 4 %) and others (n = 49, 24 %). All patients included in the study had surgical intervention in the form of decompression and stabilisation. Posterior decompression and stabilisation was performed in 171 patients (with vertebrectomy in 31), combined anterior and posterior approaches were used in 18 patients and 12 had an anterior approach only. The overall complication rate was 19 % (39/201)--the most common being wound infection (n = 15, 8 %). There was no difference in the neurological outcome (Frankel grade) between Groups 1 and 2 (p = 0.34) or Groups 2 and 3 (p = 0.70). However, there was a significant difference between Groups 1 and 3 (p = 0.001), with Group 3 having a significantly better neurological outcome. Median survival was 93 days in Group 1, 229 days in Group 2 and 875 days in Group 3 (p = 0.001). The predictive value between the actual and predicted survival was 64 % (Group 1), 64 % (Group 2) and 69 % (Group 3). The overall predictive value of the revised Tokuhashi score using Cox regression for all groups was 66 %. CONCLUSION We would conclude that although the predictive value of the Tokuhashi score in terms of survival time is at best modest (66 %), the fact that there were statistically significant differences in survival between the groups looked at in this paper indicates that the scoring system, and the components which it consists of, are important in the evaluation of these patients when considering surgery.
Collapse
Affiliation(s)
- N A Quraishi
- Centre for Spinal Studies and Surgery, Queens Medical Centre, Campus of Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7 2UH, UK.
| | | | | | | | | | | | | |
Collapse
|
22
|
Quraishi NA, Rajagopal TS, Manoharan SR, Elsayed S, Edwards KL, Boszczyk BM. Effect of timing of surgery on neurological outcome and survival in metastatic spinal cord compression. Eur Spine J 2012; 22:1383-8. [PMID: 23275041 DOI: 10.1007/s00586-012-2635-y] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Revised: 12/08/2012] [Accepted: 12/16/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE Metastatic spinal cord compression (MSCC) requires expeditious treatment. While there is no ambiguity in the literature about the urgency of care for patients with MSCC, the effect of timing of surgical intervention has not been investigated in detail. The objective of our study was to investigate whether or not the 'timing of surgery' is an important factor in survival and neurological outcome in patients with MSCC. METHODS All patients with MSCC presenting to our unit from October 2005 to March 2010 were included in this study. Patients were divided into three groups-those who underwent surgery within 24 h (Group 1, n = 45), between 24 and 48 h (Group 2, n = 23) and after 48 h (Group 3, n = 53) from acute presentation of neurological symptoms. The outcome measures studied were neurological outcome (change in Frankel grade post-operatively), survival (survival rate and median survival in days), incidence of infection, length of stay and complications. RESULTS Patients' age, gender, revised Tokuhashi score, level of spinal metastasis and primary tumour type were not significantly different between the three groups. Greatest improvement in neurology was observed in Group 1, although not significantly when compared against Group 2 (24-48 h; (p = 0.09). When comparisons of neurological outcome were performed for all patients having surgery within 48 h (Groups 1 and 2) versus after 48 h (Group 3), the Frankel grade improvement was significant (p = 0.048) favouring surgery within 48 h of presentation. There was a negative correlation (-0.17) between the delay in surgery and the immediate neurological improvement, suggesting less improvement in those who had delayed surgery. There was no difference in length of hospital stay, incidence of infection, post-operative complications or survival between the groups. CONCLUSIONS Our results show that surgery should be performed sooner rather than later. Furthermore, earlier surgical treatment within 48 h in patients with MSCC resulted in significantly better neurological outcome. However, the timing of surgery did not influence length of hospital stay, complication rate or patient survival.
Collapse
Affiliation(s)
- N A Quraishi
- Centre for Spinal Studies and Surgery, Queens Medical Centre Campus of Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7 2UH, UK.
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
The glucagon-like peptide-1 receptor agonists, exenatide and liraglutide, offer a unique mechanism in the treatment of type 2 diabetes mellitus (T2DM) as part of the incretin system. Their mechanism of action is to increase insulin secretion, decrease glucagon release, reduce food intake, and slow gastric emptying. They target postprandial blood glucose values and have some effect on fasting levels as well. In addition, they promote weight loss and may help to preserve β-cell function, both major problems in T2DM patients. Changes in hemoglobin A1c are similar to those produced by other T2DM agents, including thiazolidinediones, low-dose metformin, and sulfonylureas, and better than those caused by α-reductase inhibitors and dipeptidyl peptidase-4 inhibitors. These agents have been safely studied in combination with metformin, sulfonylureas, meglitinides, thiazolidinediones, and insulin therapy. Overall, data are limited for head-to-head comparisons, but it appears that liraglutide may have better efficacy and tolerability compared with exenatide; however, more studies are needed. They are overall well tolerated, with the main adverse events being similar to those with metformin (gastrointestinal intolerances that are transient and dose dependent). However, patients must be monitored for pancreatitis as a rare but possible side effect. For T2DM patients willing to use an injectable agent, exenatide and liraglutide offer another therapeutic option to control hyperglycemia with the potential for weight loss and may be combined with other agents safely.
Collapse
Affiliation(s)
- Krystal L Edwards
- School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA.
| | | | | | | |
Collapse
|
24
|
Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, Collins LJ, Brilakis ES, Banerjee S. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med 2012; 13:141.e1-5. [PMID: 21856249 DOI: 10.1016/j.carrev.2011.06.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2011] [Revised: 06/01/2011] [Accepted: 06/03/2011] [Indexed: 11/17/2022]
Abstract
BACKGROUND Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population. RESULTS A total of 18 patients with a median age of 66 years were identified. All patients had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery; 83% had three-vessel coronary artery disease, with left main disease present in 39% of patients. Prior to initiating ranolazine, antianginal use consisted of beta blockers (94%), long-acting nitrates (83%) and calcium channel blockers (61%). Median blood pressure (116.2/61.8 mmHg) and pulse (65 beats per min) were controlled. Median preranolazine angina episodes and sublingual nitroglycerin (SLNTG) doses per week were 14 and 10, respectively, with a Canadian Cardiovascular Society (CCS) angina grade of III-IV in 67% of patients. After initiation of ranolazine, median angina episodes per week and SLNTG doses used per week decreased to 0.7 and 0, respectively, with CCS grade of III-IV declining to 17%. Of the 18 subjects enrolled, 44% had complete resolution of angina episodes. CONCLUSION The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.
Collapse
Affiliation(s)
- R Shane Greene
- Veterans Affairs North Texas Health Care System, Dallas, TX 75216, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Irons BK, Weis JM, Stapleton MR, Edwards KL. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Curr Diabetes Rev 2012; 8:169-82. [PMID: 22429011 DOI: 10.2174/157339912800564007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Revised: 11/28/2011] [Accepted: 01/16/2012] [Indexed: 11/22/2022]
Abstract
Dipeptidyl peptidase -4 inhibitors represent a novel way to augment the incretin system and one of the newest class of medications in the treatment of type 2 diabetes mellitus. Their mechanism of action is to decrease the inactivation of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, both of which are involved in maintaining euglycemia subsequent to carbohydrate intake. Currently investigated agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. Each agent has been shown to provide significant improvements in glycemic control compared to placebo. They are effective when added to other oral diabetes agents and in the cases of sitagliptin, vildagliptin, and alogliptin in addition to insulin. These agents may not provide as significant improvement in glucose concentrations as some other medications including metformin, thiazolidinediones, or glucagon-like peptide 1 agonists. The lack of head to head clinical data comparing the various dipeptidyl peptidase 4 inhibitors does not allow for specific recommendations if one agent is more effective or safer than another within the class. Their side effect profile suggests they are very well tolerated and have few drug interactions. For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naive patients as well as those not optimally controlled on other diabetes medications.
Collapse
Affiliation(s)
- Brian K Irons
- Ambulatory Care Texas Tech University Health Sciences Center, School of Pharmacy, 3601 4th St. Lubbock, TX 79430, USA.
| | | | | | | |
Collapse
|
26
|
Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J. Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology 2011; 78:55-61. [PMID: 22170881 DOI: 10.1212/wnl.0b013e31823ed101] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid β (Aβ) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of Aβ and tau as markers of early or presymptomatic PD. METHODS CSF Aβ42, total tau, and phosphorylated tau were measured with Luminex assays in 26 LRRK2 mutation carriers, who were either asymptomatic (n = 18) or had a phenotype resembling sporadic PD (n = 8). All patients also underwent PET scans with 18F-6-fluoro-l-dopa (FD), 11C-(±)-α-dihydrotetrabenazine (DTBZ), and 11C-d-threo-methylphenidate (MP) to measure dopaminergic function in the striatum. The levels of CSF markers were then compared to each PET measurement. RESULTS Reduced CSF Aβ42 and tau levels correlated with lower striatal dopaminergic function as determined by all 3 PET tracers, with a significant association between Aβ42 and FD uptake. When cases were restricted to carriers of the G2019S mutation, the most common LRRK2 variant in our cohort, significant correlations were also observed for tau. CONCLUSIONS The disposition of Aβ and tau is likely important in both LRRK2-related and sporadic PD, even during early phases of the disease. A better understanding of their production, aggregation, and degradation, including changes in their CSF levels, may provide insights into the pathogenesis of PD and the potential utility of these proteins as biomarkers.
Collapse
Affiliation(s)
- J O Aasly
- Department of Neurology, St. Olav’s University Hospital, Trondheim, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, Collins LJ, Brilakis ES, Banerjee S. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovascular Revascularization Medicine 2011. [DOI: 10.1016/j.carrev.2011.04.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Edwards KL, Lemke AA, Trinidad SB, Lewis SM, Starks H, Quinn Griffin MT, Wiesner GL. Attitudes toward genetic research review: results from a survey of human genetics researchers. Public Health Genomics 2011; 14:337-45. [PMID: 21487211 PMCID: PMC3221257 DOI: 10.1159/000324931] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2010] [Accepted: 02/04/2011] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Researchers often relate personal experiences of difficulties and challenges with Institutional Review Board (IRB) review of their human genetic research protocols. However, there have been no studies that document the range and frequency of these concerns among researchers conducting human genetic/genomic studies. METHODS An online anonymous survey was used to collect information from human genetic researchers regarding views about IRB review of genetic protocols. Logistic regression was used to test specific hypotheses. Results from the national online survey of 351 human genomic researchers are summarized in this report. RESULTS Issues involving considerable discussion with IRBs included reconsent of subjects (51%), protection of participants' personal information (39%) and return of results to participants (34%). Over half of the participants had experienced one or more negative consequences of the IRB review process and approximately 25% had experienced one or more positive consequences. Respondents who had served on an IRB were about 80% more likely to report positive consequences of IRB review than their colleagues who had never served on an IRB (p = 0.03). Survey responses were mixed on the need for reconsent before data sharing and risks related to participant reidentification from genomic data. CONCLUSION The results from this study provide important perspectives of researchers regarding genetic research review and show lack of consensus on key research ethics issues in genomic research.
Collapse
Affiliation(s)
- K L Edwards
- Department of Epidemiology, University of Washington, Seattle, WA 98115, USA.
| | | | | | | | | | | | | |
Collapse
|
29
|
Edwards KL, Riche DM, Stroup JS, Goldman-Levine JD, Padiyara RS, Cross LB, Kane MP. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2010; 30:955-65. [PMID: 20795850 DOI: 10.1592/phco.30.9.955] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.
Collapse
Affiliation(s)
- Krystal L Edwards
- Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA.
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
REASONS FOR PERFORMING STUDY Maximally exercising horses achieve mean pulmonary artery pressures (Ppa(mean)) that exceed the minimum threshold (75 mmHg) estimated for pulmonary capillary rupture and exercise-induced pulmonary haemorrhage (EIPH). EIPH is not expected to occur during moderate submaximal exercise (i.e. 40-60% VO2max) since Ppa(mean) remains well below this threshold. HYPOTHESIS Prolonged submaximal exercise (trotting) would precipitate locomotory respiratory uncoupling and cause EIPH. This would be present as a result of the most negative intrapleural pressures (as estimated by the minimum oesophageal pressure; Poes(min)) occurring simultaneously with the most positive Ppa (Ppa(peak)) to produce estimated maximal pulmonary artery transmural pressures (PATMPmax) that surpass the EIPH threshold. METHODS Five Thoroughbred horses trotted to fatigue (approximately 25 min) at 5 m/sec on a 10% incline. Ventilation (V(E)), Poes, and Ppa were measured at 5 min intervals, and bronchoalveolar lavage (BAL) red blood cells (RBCs) were quantified 45 min post exercise. RESULTS BAL revealed an increased EIPH (rest: 2.0 +/- 1 x 10(5), exercise: 17 +/- 10 x 10(5) RBCs/ml BALF; P<0.05), despite the highest Ppamean reaching only mean +/- s.e. 55 +/- 3 mmHg, while V(E), tidal volume and Poes(min) approached 70-80% of the values achieved at maximal running speeds (10% incline: 12-13 m/sec) by these same horses. The resulting PATMPmax was well above the level considered causative of EIPH. CONCLUSIONS The finding of significant EIPH during submaximal exercise broadens the spectrum of performance horses susceptible to EIPH and supports studies that suggest that extravascular factors are of primary importance in the aetiology of EIPH. POTENTIAL RELEVANCE Consideration of strategies such as the equine nasal strip for reducing negative extravascular pressures is warranted even for exercise at moderate intensities.
Collapse
Affiliation(s)
- T S Epp
- Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
BACKGROUND The aim of this paper was to investigate variations in childhood obesity globally and spatially at the micro-level across Leeds. METHODS Body mass index data from three sources were used. Children were aged 3-13 years. Obesity was defined as above the 98th centile (British reference dataset). The data were analysed by age group and gender, then tested for significant micro-level hot spots of childhood obesity using a spatial scan statistic and a two-level multilevel model. RESULTS Older children (13 years) were 2.5 times (95% CI 2.1 to 3.1) more likely to be obese than younger children (3 years). Childhood obesity was significantly associated with deprived and affluent areas. 'Blue collar communities,' 'Constrained by circumstances' and 'Multicultural' had significantly higher (relative risk (RR): 1.1, 1.2, 1.2; 95% CI 1.0 to 1.2, 1.1 to 1.2, 1.1 to 1.3, respectively) obesity levels, and 'Typical traits' and 'Prospering suburbs' had significantly lower (RR: 0.9, 0.8; 95% CI 0.8 to 1.0, 0.7 to 0.9, respectively) obesity levels. In the unadjusted model, obesity 'hot spots' were found in deprived (RR 1.5) and affluent (RR 6.1) areas. After adjusting for demographic covariates, hot spots were found only in affluent areas (RR 1.6 to 1.9), and cold spots in affluent (RR 1.3 to 4.4) and deprived (RR up to 1.1) areas. CONCLUSION These results suggest there is either a spread of obesity across socio-economic groups and/or something special about the high-/low-prevalence areas that affects the likelihood of obesity. The microlevel spatial analyses displayed the variations in obesity across Leeds thoroughly, identifying high-risk populations.
Collapse
Affiliation(s)
- K L Edwards
- Centre of Epidemiology and Biostatistics, Room 8.49, Worsley Building, University of Leeds, Leeds LS2 9JT, UK.
| | | | | | | |
Collapse
|
32
|
Edwards KL, Clarke GP, Ransley JK, Cade J. The neighbourhood matters: studying exposures relevant to childhood obesity and the policy implications in Leeds, UK. J Epidemiol Community Health 2009; 64:194-201. [DOI: 10.1136/jech.2009.088906] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Edwards KL, Alvarez C, Irons BK, Fields J. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008; 28:506-21. [PMID: 18363534 DOI: 10.1592/phco.28.4.506] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Patients with type 2 diabetes mellitus often begin treatment by taking oral agents, usually metformin or a sulfonylurea, and then progress to the combination of these two agents. Most patients often require three or more agents or a change to an insulin regimen. However, no guidelines are available to aid the clinician in the decision-making process for selecting the third agent. Many options are available for additional therapy, including thiazolidinediones, intermediate- and long-acting insulins, exenatide, and dipeptidyl peptidase-4 inhibitors. Although the American Diabetes Association recommends metformin as first-line therapy, it does not give exact specifications for second- and third-line agents but only summarizes clinical data and options about each therapeutic drug class. Guidelines from the American College of Endocrinology and American Association of Clinical Endocrinologists recommend several options depending on the patient's hemoglobin A(1c) level. Therefore, a standard of care cannot be provided; rather, clinicians must evaluate each patient to ascertain that patient's optimum therapy. In doing so, clinicians need to be familiar with the efficacy, safety, and cost of each agent.
Collapse
Affiliation(s)
- Krystal L Edwards
- School of Pharmacy, Texas Tech University Health Sciences Center, Department of Pharmacy Practice, Veterans Administration North Texas Health Care System, Dallas, TX 75216, USA.
| | | | | | | |
Collapse
|
34
|
Chastain LM, Bain AM, Edwards KL, Bedimo R, Busti AJ. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol 2007; 1:634-9. [PMID: 21291706 DOI: 10.1016/j.jacl.2007.10.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 10/01/2007] [Accepted: 10/11/2007] [Indexed: 12/13/2022]
Abstract
BACKGROUND Abnormalities in lipid metabolism are a well-described consequence of human immunodeficiency virus (HIV) infection being treated with highly active antiretroviral therapies (HAART). OBJECTIVE The purpose of this study is to evaluate the lipid-lowering efficacy and safety of ezetimibe added to existing hydroxy methylglutaryl coenzyme A reductase (statin) therapy in HIV-infected patients with hyperlipidemia. METHODS This is a retrospective study utilizing a comprehensive electronic patient registry to identify all adult HIV-infected patients seen at the Dallas Veterans Affairs (VA) Medical Center during a 4-year period from October 1, 2002 through October 1, 2006. RESULTS A total of 26 HIV-infected patients initiated on ezetimibe 10 mg were identified, with 14 adult males meeting strict criteria for inclusion. Median age was 54 years (interquartile range [IQR], 45-59) with a median duration of HIV of 13 years, CD4 count of 513 cells/mm(3) (IQR, 289-736), and 9 of 14 patients had undetectable viral loads at baseline. Initiation of ezetimibe 10 mg resulted in a significant decrease in total cholesterol (TC) from baseline (-12.9%, P = 0.001); low-density lipoprotein cholesterol (LDL-C; -25.7%, P = 0.001); and non-high-density lipoprotein cholesterol (non-HDL-C; -23.9%, P = 0.001). There was also a nonsignificant decrease in triglycerides (15.8%, P = 0.43), and an increase in number of patients achieving National Cholesterol Education Program/Adult Treatment Panel III goal for LDL-C after initiation of ezetimibe (+20.9%, P = 0.125). These improvements occurred without adverse effects or changes in virologic and immunologic control. CONCLUSION Addition of ezetimibe to existing statin therapy in HIV-infected VA patients treated with HAART significantly reduces TC, LDL-C, and non-HDL-C concentrations without apparent side effects or compromising of virologic control.
Collapse
Affiliation(s)
- Lisa M Chastain
- Texas Tech University Health Sciences Center School of Pharmacy, Dallas/Ft. Worth Regional Campus, 4500 S. Lancaster Road, Building 7, Dallas, TX 75216, USA; North Texas Veterans Affairs Health Care Systems, Dallas, TX 75216, USA
| | | | | | | | | |
Collapse
|
35
|
Greene RS, Escobar Quinones M, Edwards KL. Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patients. ACTA ACUST UNITED AC 2007; 5:130-4. [PMID: 25214929 PMCID: PMC4154747 DOI: 10.4321/s1886-36552007000300006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Thiazide diuretics are effective antihypertensive medications shown to reduce the risk of cardiovascular events and stroke. Despite being the preferred choice for uncomplicated essential hypertension, thiazide diuretics continue to be underutilized.
Collapse
|
36
|
Edwards KL, Hall RG, Ceja ME. Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature. J Pharm Pract 2007. [DOI: 10.1177/0897190007303053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Gatifloxacin, a broad-spectrum fluoroquinolone, has recently been voluntarily withdrawn by Bristol-Myers Squibb from the market secondary to dysglycemic events associated with this agent. Risk factors for this adverse event include diabetes and those who are elderly (65 years of age or older), have renal insufficiency, or take glucose altering medications. The mechanism for this adverse reaction is not fully understood. However, it is theorized that there is an association between accumulation of gatifloxacin (particularly in elderly patients or those with renal insufficiency) and dysglycemic events with gatifloxacin. A review of the literature found 13 reported cases of hyperglycemia induced by gatifloxacin and 2 clinical trials evaluating gatifloxacin's association with hyperglycemia. Similarly to other reported cases, the authors' 4 outpatients were initiated on gatifloxacin therapy and subsequently had developed hyperglycemia during gatifloxacin therapy. Prior to the multiple observations of dysglycemias associated with gatifloxacin, this medication was widely used and thought to have an excellent safety profile. Hence, clinicians should be vigilant and exercise caution with newly approved medications.
Collapse
Affiliation(s)
- Krystal L. Edwards
- Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas,
| | - Ronald G. Hall
- Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas
| | - Maria Estela Ceja
- Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas
| |
Collapse
|
37
|
Edwards KL, Irons BK, Xu T. Coste-efectividad de la insulina de acción intermedia o larga contra Exenatide en pacientes con diabetes mellitus tipo 2 no óptimamente controlados con antidiabéticos orales. Pharm Pract (Granada) 2006. [DOI: 10.4321/s1885-642x2006000300005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
38
|
Zhang C, Austin MA, Edwards KL, Farin FM, Li N, Hsu L, Srinouanprachanh SL, Williams MA. Functional variants of the lipoprotein lipase gene and the risk of preeclampsia among non-Hispanic Caucasian women. Clin Genet 2006; 69:33-9. [PMID: 16451134 DOI: 10.1111/j.1399-0004.2005.00541.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Hypertriglyceridemia is an important pathophysiologic feature of preeclampsia, a common vascular disorder of pregnancy. Three well-documented functional variants (N291S, S447X, and D9N) of the lipoprotein lipase gene were related to hypertriglyceridemia. Results from the only two studies concerning the relationship between these variants and preeclampsia risk have been inconsistent. We investigated this relationship in a case-control study including 144 preeclamptic and 290 normotensive pregnant women (all non-Hispanic Caucasians). We estimated odds ratios (OR) and 95% confidence intervals (CI) adjusted for maternal age, pre-pregnancy body mass index, and parity. After adjusting for covariates, women with the 291 N/S or S/S genotype had significantly increased risk of preeclampsia (OR 6.9, 95% CI 1.9-25.4) compared with women with the common 291N/N genotype. The 447 S/X or X/X genotype was not significantly associated with preeclampsia risk. The frequency of the 9N variant allele was 1.8% in controls, while this allele was not observed among cases. Haplotype 9D/291S/447S was strongly associated with higher risk of preeclampsia as compared with the most common haplotype 9D/291N/447S (adjusted OR 6.6, 95% CI 1.7-25.0). Results from our study support the thesis that abnormal lipid metabolism is important in the pathogenesis of preeclampsia.
Collapse
Affiliation(s)
- C Zhang
- Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy 2006; 26:168-81. [PMID: 16466323 DOI: 10.1592/phco.26.2.168] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Clinical data suggest that thiazolidinediones--specifically, rosiglitazone and pioglitazone--may improve cardiovascular risk factors through multiple mechanisms. Low insulin sensitivity has been described as an independent risk factor for coronary artery disease and cerebrovascular disease. Patients with insulin resistance often have several known risk factors, such as obesity, dyslipidemia, and hypertension. Other emerging risk factors may be prevalent in patients with insulin resistance, such as hyperinsulinemia, elevated C-reactive protein, elevated plasminogen activator inhibitor levels, and small, dense, low-density lipoproteins. The only available drug class that primarily targets insulin resistance is the thiazolidinediones. These drugs have shown efficacy in affecting surrogate markers of cardiovascular risk in patients with diabetes mellitus. Alterations in these risk factors are likely due to their effects on improving insulin sensitivity and/or glycemic control. Trials to assess whether thiazolidinediones actually reduce cardiovascular outcomes are continuing.
Collapse
Affiliation(s)
- Brian K Irons
- Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79430-8162, USA.
| | | | | | | | | |
Collapse
|
40
|
Edwards KL, Irons BK, Xu T. Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. Pharm Pract (Granada) 2006; 4:129-33. [PMID: 25214899 PMCID: PMC4156845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
OBJECTIVE To better understand exenatide's role in the treatment of type 2 diabetes, this analysis assessed its cost-effectiveness in comparison to an intermediate (NPH) and long-acting insulin (glargine). Exenatide is a recently approved medication for the treatment of type 2 diabetes for use in addition to frequently used oral diabetes medications. METHODS Two studies were identified by a Medline search (1996-Oct 2005) that were similar in study duration, baseline glycemic control, population size, and primary outcomes to appropriately assess the cost-effectiveness of either insulin in comparison to exenatide on both glycemic and weight control. RESULTS Both NPH and glargine appear to be more cost effective than exenatide with respect to glycemic control (incremental CE ratios -1,968 and - 65,520 respectively). Exenatide appears to be more cost effective for reductions in body weight than either NPH (CE ratio 235) or glargine (CE ratio 128). CONCLUSIONS Compared to intermediate and long-acting insulin therapies, exenatide does not appear to be as cost effective for the treatment of type 2 diabetes.
Collapse
Affiliation(s)
- Krystal L. Edwards
- Assistant Professor. Department of Pharmacy Practice and Veterans Administration North Texas
Health Care System. School of Pharmacy Texas Tech University Health
Sciences Center. Dallas, TX (USA)
| | - Brian K. Irons
- Division Head - Primary Care. Assistant Professor. Department of Pharmacy Practice, School of
Pharmacy. Texas Tech University Health Sciences Center. Dallas, TX
(USA)
| | - Tom Xu
- Department of Family and Community Medicine, School of Medicine. Texas Tech
University Health Sciences Center. Dallas, TX (USA)
| |
Collapse
|
41
|
Middaugh CR, Edwards KL. Recent advances in our understanding of protein conformational stability from a pharmaceutical perspective. Expert Opin Investig Drugs 2005; 7:1493-500. [PMID: 15992046 DOI: 10.1517/13543784.7.9.1493] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The marginal conformational stability of proteins has made them in some cases less than ideal candidates for pharmaceutical agents. Recent progress in our understanding of protein structure and stability has provided the opportunity to design the desired degree of stability into protein drug candidates. Modifications such as the optimisation of interior side-chain packing, the introduction of new ion-pairs, as well as the design of stabilising disulfide bridges and ligand binding sites, all offer the opportunity to produce proteins with enhanced stability properties.
Collapse
Affiliation(s)
- C R Middaugh
- Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS 66047, USA
| | | |
Collapse
|
42
|
Austin MA, Zhang C, Humphries SE, Chandler WL, Talmud PJ, Edwards KL, Leonetti DL, McNeely MJ, Fujimoto WY. Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. Ann Hum Genet 2004; 68:179-88. [PMID: 15180698 DOI: 10.1046/j.1529-8817.2004.00078.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Numerous studies have demonstrated that increased C-reactive protein (CRP) levels predict coronary heart disease, stroke, peripheral vascular disease, and diabetes, and are associated with features of the metabolic syndrome. Only three previous studies have investigated the heritability of CRP levels, primarily in samples of Caucasian families. The purpose of the present study was to estimate the magnitude of genetic influences on CRP levels, and to examine potential associations between variation in the APOE gene and CRP levels, using a sample of 562 individual Japanese Americans from 68 extended kindreds. In general, correlation coefficients between first-degree relatives for CRP were approximately 0.2, and spouse correlations did not differ from zero, consistent with genetic influences. Heritability estimates were approximately 0.3 (p < 0.01), even with adjustment for factors known to influence CRP levels. A significant relationship was seen between unadjusted CRP levels and APOE genotypes (p = 0.02), with the highest mean CRP level among epsilon2 carriers (1.20 mg/L), and nearly the same mean levels among epsilon3/epsilon3 subjects and epsilon4 carriers (0.72 and 0.74 mg/L, respectively). However, this relationship was diminished with adjustment for covariates (p = 0.07). These results demonstrate the presence of both genetic and environmental effects on CRP levels among Asian Americans, and additional studies are needed to determine if the APOE gene contributes to these genetic influences.
Collapse
Affiliation(s)
- M A Austin
- Department of Epidemiology, School of Public Health and Community Medicine, Box 357236, University of Washington, Seattle, WA 98195-7236, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis 2001; 159:471-81. [PMID: 11730829 DOI: 10.1016/s0021-9150(01)00528-7] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In order to characterize the lipoprotein abnormalities in familial combined hyperlipidemia (FCHL) and to describe factors associated with the stability of the FCHL phenotype during 20-year follow-up, 287 individuals from 48 families with FCHL originally identified in the early 1970s (baseline) were studied. Hyperlipidemia was defined as lipid-lowering medication use, or > or =age- and sex-specific 90th percentile for triglycerides or cholesterol. Triglyceride, cholesterol and medical history data were obtained at baseline and 20-year follow-up. Additional follow-up measures included HDL-C, LDL-C, LDL particle size, lipoprotein(a), apolipoprotein (apo) A-I, apoB, and apoE polymorphism. Longitudinally, two-thirds of relatives were consistently normolipidemic or hyperlipidemic, and one third were discordant for hyperlipidemic status at baseline and 20-year follow-up. Individuals with hyperlipidemia at baseline and/or follow-up had higher apoB levels than those with consistently normal lipids (P<0.05), whereas small LDL size was associated with concurrent hyperlipidemia. Among individuals who were normolipidemic at baseline, the following variables were independently associated with development of hyperlipidemia over 20 years: older age at baseline, male sex, greater increase in BMI during follow-up, and apoE alleles epsilon 2 or epsilon 4. In conclusion, apoB is associated with hyperlipidemia and apoE polymorphism is associated with later onset of hyperlipidemia in FCHL.
Collapse
Affiliation(s)
- M J McNeely
- Department of Medicine, School of Medicine, University of Washington, Box 356429, Seattle, WA 98195, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Kim H, Marcovina SM, Edwards KL, McKnight B, Bradley CM, McNeely MJ, Psaty BM, Motulsky AG, Austin MA. Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia. Clin Genet 2001; 60:188-97. [PMID: 11595020 DOI: 10.1034/j.1399-0004.2001.600304.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Most but not all epidemiologic studies have shown that lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD). Lp(a) levels are also strongly genetically influenced. The purpose of this study was to evaluate the association between Lp(a) levels in adult offspring and parental CVD mortality in 61 kindreds with familial forms of hyperlipidemia. The study sample consisted of offspring-parent pairs in which offspring had fasting Lp(a) measurements and parents had 20-year vital status data and standardized cause-of-death classification if deceased. Linear regression analyses, using a robust variance estimator, were performed separately for 241 offspring with known maternal history (114 mothers) and 194 offspring with known paternal history (93 fathers). Maternal history of CVD mortality was significantly (p=0.004) associated with 2.4-fold higher median Lp(a) levels in offspring compared with those with no maternal history, independent of diabetes, lipid-lowering medications and hormone use. No association was observed between paternal CVD mortality and offspring Lp(a) levels (p=0.505). Adjusting for apolipoprotein(a) kringle 4 number did not alter these parent-specific associations. In conclusion, Lp(a) levels in offspring may be associated with maternal but not paternal history of CVD mortality. This parent-specific finding needs to be confirmed in other samples of high-risk families.
Collapse
Affiliation(s)
- H Kim
- Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Edwards KL, Kueltzo LA, Fisher MT, Middaugh CR. Complex effects of molecular chaperones on the aggregation and refolding of fibroblast growth factor-1. Arch Biochem Biophys 2001; 393:14-21. [PMID: 11516157 DOI: 10.1006/abbi.2001.2472] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Fibroblast growth factor one (FGF-1) exists in a molten globule (MG)-like state under physiological conditions (neutral pH, 37 degrees C). It has been proposed that this form of the protein may be involved in its atypical membrane transport properties. Macromolecular chaperones have been shown to bind to MG states of proteins as well as to be involved in protein membrane transport. We have therefore examined the effect of such proteins on the aggregation and refolding of FGF-1 to evaluate whether they might play a role in FGF-1 transport. The proposed chaperone alpha-crystallin was found to strongly inhibit the aggregation of the MG state of FGF-1. Curiously, two other proteins of similar size and charge (thyroglobulin and a monoclonal IgM immunoglobulin) with no previously reported chaperone properties were also found to have a related effect. In contrast, the chaperone GroEL/ES induced further aggregation of MG-like FGF-1 but had no effect on the native conformation. Both chaperones stimulated refolding to the native state (25 degrees C) but had no detectable effect when FGF-1 was refolded to the MG state (37 degrees C). This suggests that disordered intermediates are present in the folding pathways of the native and MG-like FGF conformations which differ from the MG-like state induced under physiological conditions. FGF-1 does, therefore, interact with molecular chaperones, although this may involve both the MG and the native states of the protein.
Collapse
Affiliation(s)
- K L Edwards
- Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047, USA
| | | | | | | |
Collapse
|
46
|
Kamigaki AS, Siscovick DS, Schwartz SM, Psaty BM, Edwards KL, Raghunathan TE, Austin MA. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol 2001; 153:939-45. [PMID: 11384949 DOI: 10.1093/aje/153.10.939] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Previous studies of middle-aged men have shown a univariate association between low density lipoprotein (LDL) particle diameter (size) and coronary heart disease, but this association has yet to be examined in younger women. Using a subsample from a population-based case-control study of women living in western Washington State, the authors examined the association between LDL particle size and risk of early-onset myocardial infarction (MI) in 1992-1995. Gradient gel electrophoresis was used to characterize LDL subclasses in nonfasting blood samples from 72 MI cases and 159 controls aged 20-44 years. Mean LDL particle size in cases was significantly smaller compared with controls (26.4 vs. 26.9 nm, p < 0.001), with an odds ratio of 2.3 (p < 0.0001) for a 1-nm smaller LDL particle size. These results were independent of age, menopausal status, smoking, diabetes, hypertension, and LDL cholesterol (odds ratios = 1.9-2.3 for a 1-nm smaller LDL particle size, all p < 0.02) but were not independent of body mass index, high density lipoprotein cholesterol, or triglyceride (odds ratios = 1.4, 1.4, and 1.1, respectively; all p > 0.05). Therefore, in age-adjusted analyses, smaller LDL particle size was associated with MI in young women, but the risk was attenuated after adjustments for metabolic factors related to both LDL particle size and MI.
Collapse
Affiliation(s)
- A S Kamigaki
- Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195-7236, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Edwards KL, Talmud PJ, Newman B, Krauss RM, Austin MA. Lipoprotein candidate genes for multivariate factors of the insulin resistance syndrome: a sib-pair linkage analysis in women twins. Twin Res 2001; 4:41-7. [PMID: 11665324 DOI: 10.1375/1369052012137] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The insulin resistance syndrome (IRS) is characterized by a combination of interrelated coronary heart disease risk factors, including low high-density lipoprotein cholesterol (HDLC) levels, obesity and increases in triglyceride (TG), systolic and diastolic blood pressure (BP), small low-density lipoprotein particles (LDL-size), and fasting and postload plasma insulin and glucose. Using factor analysis, we previously identified multivariate factors based on data from women participating in the Kaiser Permanente Women Twins Study: 1) Weight/Fat, 2) Insulin/Glucose, 3) Lipids, and 4) BP. The purpose of this study is to evaluate evidence for genetic linkage between the multivariate factors and candidate genes. Quantitative sib-pair analysis based on the factor scores with markers for 9 candidate genes was carried out based on data from 126 pairs of dizygotic (DZ) women twins from the second exam of the Kaiser Permanente Women Twins study. Suggestive evidence for linkage was found for the Weight/fat factor and the Apo E gene (p = 0.01), and stronger evidence for linkage with the Lipid factor and the cholesterol ester transfer protein (p = 0.002) gene. Therefore, the CETP gene appears to influence covariation in LDL size, TG, and HDL, and may account for a portion of the well-established statistical and metabolic associations observed between these risk factors.
Collapse
Affiliation(s)
- K L Edwards
- Department of Epidemiology, Box 357236, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA.
| | | | | | | | | |
Collapse
|
48
|
Grillo AO, Edwards KL, Kashi RS, Shipley KM, Hu L, Besman MJ, Middaugh CR. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 2001; 40:586-95. [PMID: 11148054 DOI: 10.1021/bi001547t] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Aggregation of proteins is a major problem in their use as drugs and is also involved in a variety of pathological diseases. In this study, biophysical techniques were employed to investigate aggregate formation in the pharmaceutically important protein, recombinant human factor VIII (rhFVIII). Recombinant human factor VIII incubated in solution at 37 degrees C formed soluble aggregates as detected by molecular sieve chromatography and dynamic light scattering. This resulted in a corresponding loss of biological activity. Fluorescence and CD spectra of the thermally stressed rhFVIII samples did not, however, suggest significant differences in protein conformation. To identify conformational changes in rhFVIII that may be involved in rhFVIII aggregation, temperature and solutes were used to perturb the native structure of rhFVIII. Far-UV CD and FTIR studies of rhFVIII as a function of temperature revealed conformational changes corresponding to an increase in intermolecular beta-sheet content beginning at approximately 45 degrees C with significant aggregation observed above 60 degrees C. Fluorescence and DSC studies of rhFVIII also indicated conformational changes initiating between 45 and 50 degrees C. An increase in the exposure of hydrophobic surfaces was observed beginning at approximately 40 degrees C, as monitored by increased binding of the fluorescent probe, bis-anilinonaphthalene sulfonic acid (bis-ANS). Perturbation by various solutes produced several transitions prior to extensive unfolding of rhFVIII. In all cases, a common transition, characterized by an increase in the wavelength of the fluorescence emission maximum of rhFVIII from approximately 330 to 335 nm, was observed during thermal and solute perturbation of factor VIII. Moreover, this transition was correlated with an increased association of factor VIII upon incubation at 37 degrees C in the presence of various solutes. These results suggest that association of rhFVIII in solution was initiated by a small transition in the tertiary structure of the protein which produced a nucleating species that led to the formation of inactive soluble aggregates.
Collapse
Affiliation(s)
- A O Grillo
- Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66046 and Hyland Immuno Division, Baxter Healthcare Corporation, Duarte, California 91010, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, Sharp DS. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000; 86:412-6. [PMID: 10946034 DOI: 10.1016/s0002-9149(00)00956-5] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Decreased low-density lipoprotein (LDL) particle size is associated with coronary heart disease (CHD) risk among middle-aged Caucasian populations, and has been consistently correlated with increased plasma levels of triglyceride and decreased levels of high-density lipoprotein (HDL) cholesterol. This study examines whether these risk factors predict CHD among older Japanese-American men. With use of the Honolulu Heart Program Lipoprotein Exam 3 (1980 to 1982) as baseline, and 12-year follow-up for CHD events, a nested, case-control study was designed. One hundred forty-five incident CHD cases were identified and matched to 2 controls each. LDL particle diameter (size) was determined by gradient gel electrophoresis. A 10-angstrom (A) decrease in LDL size at baseline was associated with increased risk of incident CHD (relative risk 1.28, 95% confidence interval 1.01 to 1.63). After adjustment for baseline risk factors, the LDL size association was no longer statistically significant (relative risk 1.13, 95% confidence interval 0.86 to 1.49). When principal components analysis was used to define a composite variable for LDL size, triglycerides, and HDL cholesterol, this component predicted CHD independent of smoking, alcohol consumption, physical activity, body mass index, hypertension, diabetes, and beta-blocker use (p <0.01). Therefore, this prospective analysis of data from older, Japanese-American men demonstrated that decreased LDL size is a univariate predictor of incident CHD, and that a composite risk factor of LDL size, triglyceride, and HDL cholesterol was a risk factor for CHD independent of other risk factors.
Collapse
Affiliation(s)
- M A Austin
- Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Friedlander Y, Talmud PJ, Edwards KL, Humphries SE, Austin MA. Sib-pair linkage analysis of longitudinal changes in lipoprotein risk factors and lipase genes in women twins. J Lipid Res 2000; 41:1302-9. [PMID: 10946018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Based on longitudinal twin data in women, we have previously demonstrated a genetic influence on changes in lipoprotein risk factors, blood pressure measurements, and body mass index over a decade. The present study examined the linkage between changes in lipoprotein variables and candidate genes encoding the hormone-sensitive lipase (HSL), hepatic lipase (HL), and lipoprotein lipase (LPL). The sample consisted of 126 dizygotic (DZ) pairs of women twins who participated in the two examinations of the Kaiser Permanente Women Twins Study, performed a decade apart. Using quantitative sib-pair linkage analysis, a linkage was demonstrated between the locus for hormone-sensitive lipase and age-adjusted changes in plasma triglyceride (P = 0.015), which became more significant after adjustment for environmental factors and the exam-1 level (P = 0.005). There was also evidence suggesting linkage between the locus for hepatic lipase and changes in triglyceride (P = 0.023), but no linkage was detected for lipoprotein lipase and changes of lipid levels with time. These findings suggest that variation at these candidate gene loci may underlie a portion of the intraindividual variations in these coronary heart disease (CHD) risk factors, and that studies to identify the functional variants could provide new insights into genetic susceptibility to cardiovascular disease.
Collapse
Affiliation(s)
- Y Friedlander
- Department of Social Medicine, School of Public Health, Hadassah-University Hospital, 91120 Jerusalem, Israel
| | | | | | | | | |
Collapse
|